This board acts as a portal for PVCT investors, and retains the right to refuse service to individuals not in compliance with reasonable, responsible, and intelligible posting practices.
...RECENT IN THE NEWS JULY 31 07...
Knoxville lab develops new drug to help destroy cancer
Note make sure to click on the video link above the pictures
wate.com
--------------------------------------------------------------
Letter from the CEO Craig Dee's
We are a group of dedicated and entrepreneurial scientists, working together for the past 10 years, engaged in developing breakthrough technologies for cancer and other serious diseases. Our primary goal at Provectus is to develop alternative treatments that are safer, more effective, less invasive and more economical than conventional therapies.
Our Provectus Pharmatech division develops ethical pharmaceuticals for oncology and dermatology. Looking first to oncology, our novel drugs are designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing systemic side effects. In particular, our focus is on melanoma, breast and liver cancers – among the most difficult cancers to treat using conventional methods. We are very excited about the Phase I clinical trials of Provecta™ that began in 2005 for melanoma and breast cancer, and we are expanding to include liver cancer patients soon.
Targeting abnormal or diseased cells is also the approach we use in designing proprietary treatments for dermatological diseases, in particular, chronic, severe cases of psoriasis, eczema and acne. We anticipate that Phase II clinical trials of our topical agent Xantryl™ for psoriasis and eczema will begin soon. In addition, certain skin cancers may be targeted and treated more safely and effectively using Xantryl™.
In addition to our core pharmaceutical work, Provectus has developed a number of intellectual properties and technologies in the areas of medical devices and biotechnologies. Rather than dilute the efforts of Pharmatech, we are actively pursuing licensure, co-development, spin-offs and joint ventures of these technologies via our divisions Provectus Devicetech and Provectus Biotech. Devicetech encompasses both cosmetic and therapeutic treatments, with key attention to developing laser-based products to treat melanoma. Biotech is concentrating on producing vaccines to prevent certain cancers and other serious diseases, as well as detecting new viruses that could be associated with the onset of such diseases.
Our fourth division, Pure-ific Corp., is prepped to be sold or spun off to further develop its over-the-counter products. We are introducing professional skincare products for disposable glove users, and novel retail products for personal hygiene. In addition, we will be introducing an OTC product for acne sufferers.
We are proud of our intellectual capital at Provectus. We hold 15 U.S. patents in the pharmaceutical, medical device and biotech fields, with 19 additional patent applications in the works.
Provectus is a significant, emerging player in the huge and growing pharmaceutical industry. We believe in our potential to improve health care worldwide, using breakthrough products that are easy to manufacture and license, and economical to use. We appreciate your interest in our company, and welcome your comments and questions.
Craig Dees, Ph.D., CEO
Provectus Pharmaceuticals
--------------------------------------------------------------
PVCT 6 months chart:
stockcharts.com
Technical analysis:
stockta.com
PVCT News:
finance.yahoo.com
CEO INTERVIEW
-------------------------
July 25, 2005
wallst.net
february 2005
ceocfointerviews.com
financialnewsusa.com
macreport.net
May 16,2006
webcast presentation at the Rodman & Renshaw 3rd annual Global Healthcare Conference in Monte carlo,Monaco
wsw.com
PVCT profiled by Allen&Caron Inc.(May 2006)
allencaron.com
PVCT Video CNBC Europe interview with CEO Craig Dees, Ph.D.
Decembre 23,2005
pvct.com
DETAILED RESEARCH REPORTS:
--------------------------------------------------------------
pvct.com
--------------------------------------------------------------
PVCT insiders transactions:
secform4.com
--------------------------------------------------------------
Drug Delivery Technology magazine special feature article "Revisiting Intralesional Delivery of Cancer Treatment", by Provectus CEO Craig Dees, Ph.D., compares Provectus’ novel cancer drugs to current cancer treatments.
pvct.com
--------------------------------------------------------------
May 17, 2007
Professor Peter Hersey, M.D. comments on PV-10 and a patient's response
Professor Peter Hersey, M.D., a professor of oncology at the University of Newcastle and Medical and Research Director of the Newcastle Melanoma Unit, comments on PV-10 and a patient's response.
Video can be viewed here.
pvct.com
This 15-minute clip follows the progress of an 86-year-old man treated with the drug. Prior to his treatment, his melanoma was so unresponsive to the current standard of care, including numerous invasive operations and toxic chemotherapy, that he was given only months to live.
Video can be viewed here.
pvct.com
--------------------------------------------------------------
Contact Info
Telephone: +1 (865) 769-4011
Fax: +1 (865) 769-4013
info@pvct.com
Mailing Address:
Provectus Pharmaceuticals, Inc.
7327 Oak Ridge Hwy
Knoxville, TN 37931 USA
Transfer Agent:
(i.e. stockholder records, transfer, change of address, etc.)
Atlas Stock Transfer
5899 South State Street, Suite # 24
Murray, UT 84107
Telephone: +1 (801) 266-7151
Fax: +1 (801) 262-0907
Investor Relations:
Joseph Kessler
The Investor Relations Group
11 Stone St., 3rd fl
New York, NY 10004
Telephone: 212-825-3210
Fax: 212-825-3229
jkessler@investorrelationsgroup.com
Public Relations:
The Investor Relations Group
Janet Vasquez
Telephone: 212-825-3210
janet@theinvestorrelationsgroup.com
Investment Advisor:
Damon Testaverde
Network 1 Financial Securities
Telephone: +1 (800) 205-8031
--------------------------------------------------------------
Share Statistics
Outstanding:
45.45 m
Float:
35.35 m
Non-Corp. Insider Hold'gs:
22.20% (as of 4/1/07)
--------------------------------------------------------------
Company Website
pvct.com |
